<DOC>
	<DOCNO>NCT00354393</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate , vinorelbine , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Radiation therapy use high-energy x-ray kill tumor cell . Cisplatin may also make tumor cell sensitive radiation therapy . Giving chemotherapy radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give combination chemotherapy without surgery chemoradiotherapy work treat patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Surgery Chemoradiotherapy Treating Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess response induction combination chemotherapy comprise methotrexate , vinorelbine ditartrate , cisplatin patient previously untreated malignant pleural mesothelioma . Secondary - Assess tolerability toxicity regimen patient . - Determine relapse-free overall survival patient treat induction combination chemotherapy without surgery hemithoracic radiation . - Assess impact induction combination chemotherapy operability surgical success . - Evaluate impact treatment regimens quality life . OUTLINE : - Induction chemotherapy : Patients receive MVP chemotherapy comprise cisplatin IV 30-60 minute day 1 vinorelbine ditartrate IV 5-10 minute methotrexate IV 5-30 minute day 8 , 15 , 22 . Treatment repeat every 28 day 2 course . Patients unresectable disease may receive 2 additional course induction chemotherapy . Patients require palliative radiotherapy progressive disease remove study . Patients resectable disease sarcomatoid histology T1-3 , N1-2 disease complete partial response induction chemotherapy proceed surgery . - Surgery : Patients extensive disease undergo palliative debulking pleurectomy decortication take study . All patient undergo thoracotomy extrapleural pneumonectomy proceed chemoradiotherapy . - Chemoradiotherapy : Beginning 6-10 week surgery , patient undergo 3-dimensional conformal intensity-modulated radiotherapy daily , 5 day week , 6 week . Patients also receive cisplatin IV 30-60 minute day 1 22 . Patients respond disease proceed adjuvant chemotherapy . - Adjuvant chemotherapy : Patients receive 2 additional course MVP chemotherapy . Quality life assess baseline , course induction chemotherapy , surgery , every 3 month thereafter . After completion study therapy , patient follow every 3 month . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant pleural mesothelioma Amenable aggressive surgical resection , deem resectable Patients potentially resectable disease must undergo mediastinoscopy establish surgical stage Resectable disease define follow : Epithelioid , mixed histology , histology otherwise specify clinical stage IIII ( T13 , N02 , M0 ) disease Sarcomatoid histology clinical stage IIII ( T13 , N0 ) disease Intraperitoneal extension , contralateral thoracic extension , distant metastasis eligible , consider unresectable Disease consider unresectable medical reason surgery decline PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm³ Platelet count &gt; 100,000/mm³ Creatinine ≤ 1.7 mg/dL Alkaline phosphatase &lt; 2 time normal AST &lt; 2 time normal Albumin &gt; 3 g/dL Bilirubin &lt; 2.0 mg/dL Patients must available compliant adequate longterm followup Not pregnant Negative pregnancy test Fertile patient must use effective contraception Patients resectable disease must adequate pulmonary function undergo surgery radiotherapy No active malignancy PRIOR CONCURRENT THERAPY : No prior surgical resection , radiation therapy , chemotherapy , immunotherapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>epithelial mesothelioma</keyword>
</DOC>